信息来源:Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial Published:March, 2024DOI:doi.org/10.1016/S...
(2023). Efficacy of dolutegravir and rilpivirine for treatment-naive HIV-1-infected individuals with K103N resistance mutation: a multicentre, open-label, randomised phase 2b trial. The Lancet HIV, 10, e466-e474. O网页链接2、文中部分内容或图片来源网络,如有侵权,请联系删除。
Rokx C, Verbon A, Rijnders B. Successful switch to rilpivirine/tenofo- vir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase in- hibitor therapy. HIV Med 2014; doi:10.1111/hiv.12157....
Rimsky, L.; Vingerhoets, J.; Van Eygen, V.; Eron, J.; Clotet, B.; Hoogstoel, A.; Boven, K.; Picchio, G. Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies: 48...
This mutation confers a high degree of resistance to both NVP and DLV and a moderate resistance to rilpivirine RPV [11]. A relatively rare mutation of Y188L was also identified in viruses from patients who have failed with NNRTI-containing regimens. Y188L was shown to be highly resistant ...